Howard Steinberg credits psychedelics for curing his burnout
Howard Steinberg’s success-driven life collapsed at 52, and after failed therapy, he used psilocybin to confront his emptiness, sparking a spiritual awakening. Psychedelics are gaining legitimacy for
Howard Steinberg built what looked like the perfect life: a high-flying career, a big house in the suburbs, and a picture-perfect marriage. Then, at 5
Read Full Story at Business Insider Mkt →Why This Matters
The narrative of the American Dream often equates success with self-worth, yet Howard Steinberg’s story exposes the hollow core of that equation. His experience underscores a growing disillusionment among high-achieving professionals who realize material triumph offers no immunity against existential emptiness. It challenges society to redefine prosperity beyond metrics of wealth and status.
Background Context
Psychedelics, once relegated to the fringes of counterculture, are undergoing a renaissance in mainstream medicine, with psilocybin leading the charge in treating depression and PTSD. The FDA’s designation of MDMA as a "breakthrough therapy" in 2017 marked a turning point, but psychedelics’ resurgence also intersects with a broader cultural reckoning over burnout and midlife crises among the professional class. Meanwhile, corporate wellness programs are quietly exploring their potential despite lingering legal and ethical hurdles.
What Happens Next
As psychedelic-assisted therapy gains regulatory approval, Steinberg’s story may embolden more high-functioning individuals to seek alternative paths to fulfillment, potentially reshaping workplace culture. Yet the scalability of these treatments remains uncertain, with questions looming over access, affordability, and the risks of commercializing sacred traditions. Watch for shifts in insurance coverage and corporate policies as the conversation evolves from stigma to legitimacy.
Bigger Picture
Steinberg’s journey reflects a broader generational shift, where younger cohorts prioritize purpose over paychecks and older ones confront the limitations of late-stage capitalism. The psychedelic renaissance aligns with this zeitgeist, offering a counterpoint to the pharmaceutical status quo while reviving Indigenous healing practices. Yet it also risks becoming another commodified quick fix unless paired with systemic change in how society defines success and well-being.
